Sanofi faces its share of headwinds like generic erosion of key drug Aubagio in all key markets and lower sales from mature products, which are hurting sales. Other headwinds include the weak ...

two studies of the drug in relapsing forms of MS – GEMINI 1 and 2 – were unable to show any improvement with tolebrutinib compared to Sanofi's current oral MS therapy Aubagio (teriflunomide ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...